drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01254 | DB08826 | 1,213 | 1,292 | [
"DDInter484",
"DDInter489"
] | Dasatinib | Deferiprone | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1213,
25,
1292
]
],
[
[
1213,
6,
2240
],
[
2240,
46,
1292
]
],
[
[
1213,
18,
2215
],
[
2215,
57,
1292
]
],
[
[
1213,
7,
7242
],
[
7242... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"BTK"
],
[
"BTK",
"{u} (Gene) is upregulated by {v} (Compound)",
"Deferipr... | Dasatinib (Compound) binds BTK (Gene) and BTK (Gene) is upregulated by Deferiprone (Compound)
Dasatinib (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Deferiprone (Compound)
Dasatinib (Compound) upregulates PHKA1 (Gene) and PHKA1 (Gene) is downregulated by Deferiprone (Compound)
Dasatinib (C... |
DB00399 | DB00945 | 963 | 1,479 | [
"DDInter1968",
"DDInter20"
] | Zoledronic acid | Acetylsalicylic acid | Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid]. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors,... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
963,
24,
1479
]
],
[
[
963,
21,
28751
],
[
28751,
60,
1479
]
],
[
[
963,
24,
1512
],
[
1512,
24,
1479
]
],
[
[
963,
24,
1448
],
[
1448... | [
[
[
"Zoledronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Zoledronic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u}... | Zoledronic acid (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Acetylsalicylic acid (Compound)
Zoledronic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases w... |
DB00776 | DB06626 | 1,335 | 263 | [
"DDInter1360",
"DDInter147"
] | Oxcarbazepine | Axitinib | Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000.[L8627,L8630,L8633] It is a structural derivative of [carbamazepine] and exerts a majority of its activity via a pharmacologically active metabolite, MHD, which exis... | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Moderate | 1 | [
[
[
1335,
24,
263
]
],
[
[
1335,
63,
1215
],
[
1215,
23,
263
]
],
[
[
1335,
24,
101
],
[
101,
23,
263
]
],
[
[
1335,
24,
392
],
[
392,
... | [
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
... | Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Axitinib
Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole... |
DB00867 | DB08882 | 1,052 | 1,281 | [
"DDInter1606",
"DDInter1070"
] | Ritodrine | Linagliptin | Adrenergic beta-agonist used to control premature labor. | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1052,
24,
1281
]
],
[
[
1052,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1052,
62,
251
],
[
251,
24,
1281
]
],
[
[
1052,
25,
868
],
[
868,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Ritodrine may cause a minor interaction that can limit clinical effects when taken with Betamethasone and Betamethasone may cause a moderate interaction that co... |
DB00390 | DB00572 | 1,252 | 85 | [
"DDInter554",
"DDInter136"
] | Digoxin | Atropine | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Minor | 0 | [
[
[
1252,
23,
85
]
],
[
[
1252,
23,
19
],
[
19,
24,
85
]
],
[
[
1252,
25,
1166
],
[
1166,
40,
85
]
],
[
[
1252,
18,
4930
],
[
4930,
... | [
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atropine"
]
],
[
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscy... | Digoxin may cause a minor interaction that can limit clinical effects when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Digoxin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron (Compound) resembl... |
DB08875 | DB08912 | 1,618 | 1,040 | [
"DDInter262",
"DDInter462"
] | Cabozantinib | Dabrafenib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1618,
24,
1040
]
],
[
[
1618,
25,
1612
],
[
1612,
62,
1040
]
],
[
[
1618,
63,
1101
],
[
1101,
23,
1040
]
],
[
[
1618,
64,
478
],
[
478... | [
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Foste... | Cabozantinib may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may ca... |
DB00562 | DB00912 | 1,014 | 473 | [
"DDInter188",
"DDInter1581"
] | Benzthiazide | Repaglinide | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1014,
24,
473
]
],
[
[
1014,
24,
1512
],
[
1512,
24,
473
]
],
[
[
1014,
63,
1645
],
[
1645,
24,
473
]
],
[
[
1014,
24,
433
],
[
433,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Me... |
DB00987 | DB09498 | 1,224 | 810 | [
"DDInter460",
"DDInter1715"
] | Cytarabine | Strontium chloride Sr-89 | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stag... | Moderate | 1 | [
[
[
1224,
24,
810
]
],
[
[
1224,
63,
552
],
[
552,
24,
810
]
],
[
[
1224,
24,
60
],
[
60,
24,
810
]
],
[
[
1224,
23,
1272
],
[
1272,
... | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
... | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Capecit... |
DB00448 | DB00880 | 1,215 | 359 | [
"DDInter1022",
"DDInter360"
] | Lansoprazole | Chlorothiazide | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
1215,
24,
359
]
],
[
[
1215,
24,
1577
],
[
1577,
1,
359
]
],
[
[
1215,
21,
28973
],
[
28973,
60,
359
]
],
[
[
1215,
24,
126
],
[
126,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Lansoprazole (Compound) causes Nephritis interstitial (Side Effect) and Nephritis interstitial (Side Effect) is caused by Chlorothiazide (... |
DB01203 | DB01364 | 699 | 22 | [
"DDInter1255",
"DDInter650"
] | Nadolol | Ephedrine | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
699,
24,
22
]
],
[
[
699,
63,
1445
],
[
1445,
1,
22
]
],
[
[
699,
6,
3576
],
[
3576,
45,
22
]
],
[
[
699,
21,
28680
],
[
28680,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Nadolol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Ephedrine (Compound)
Nadolol (Compound) causes Rash (Side Effect) and Rash (Side Effect... |
DB00009 | DB00461 | 1,271 | 598 | [
"DDInter56",
"DDInter1254"
] | Alteplase | Nabumetone | Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplas... | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Moderate | 1 | [
[
[
1271,
24,
598
]
],
[
[
1271,
25,
366
],
[
366,
24,
598
]
],
[
[
1271,
24,
1512
],
[
1512,
63,
598
]
],
[
[
1271,
25,
936
],
[
936,
... | [
[
[
"Alteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
]
],
[
[
"Alteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibati... | Alteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may caus... |
DB00099 | DB06589 | 440 | 1,250 | [
"DDInter735",
"DDInter1400"
] | Filgrastim | Pazopanib | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
440,
24,
1250
]
],
[
[
440,
24,
1419
],
[
1419,
24,
1250
]
],
[
[
440,
24,
1491
],
[
1491,
63,
1250
]
],
[
[
440,
63,
599
],
[
599,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostauri... |
DB01128 | DB01177 | 918 | 77 | [
"DDInter204",
"DDInter904"
] | Bicalutamide | Idarubicin | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
918,
24,
77
]
],
[
[
918,
6,
6017
],
[
6017,
45,
77
]
],
[
[
918,
7,
17537
],
[
17537,
57,
77
]
],
[
[
918,
21,
28931
],
[
28931,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Bicalutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compoun... | Bicalutamide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Bicalutamide (Compound) upregulates USP6NL (Gene) and USP6NL (Gene) is downregulated by Idarubicin (Compound)
Bicalutamide (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Co... |
DB00280 | DB05812 | 494 | 1,374 | [
"DDInter575",
"DDInter8"
] | Disopyramide | Abiraterone | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
494,
25,
1374
]
],
[
[
494,
6,
6943
],
[
6943,
45,
1374
]
],
[
[
494,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
494,
23,
112
],
[
112,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Disopyramide",
"{u} (Compound) binds {v} (Gene)",
"ORM1"
],
[
"ORM1",
"{u} (Gene) is bound by {v} (Compound)",
"Abirat... | Disopyramide (Compound) binds ORM1 (Gene) and ORM1 (Gene) is bound by Abiraterone (Compound)
Disopyramide (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazo... |
DB00443 | DB01136 | 251 | 772 | [
"DDInter195",
"DDInter305"
] | Betamethasone | Carvedilol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
251,
24,
772
]
],
[
[
251,
18,
3191
],
[
3191,
45,
772
]
],
[
[
251,
6,
4973
],
[
4973,
45,
772
]
],
[
[
251,
21,
29224
],
[
29224,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Betamethasone",
"{u} (Compound) downregulates {v} (Gene)",
"VEGFA"
],
[
"VEGFA",
"{u} (Gene) is bound by {v} ... | Betamethasone (Compound) downregulates VEGFA (Gene) and VEGFA (Gene) is bound by Carvedilol (Compound)
Betamethasone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound)
Betamethasone (Compound) causes Rash erythematous (Side Effect) and Rash erythematous (Side Effect) is caused by Carvedilo... |
DB00507 | DB01589 | 316 | 481 | [
"DDInter1299",
"DDInter1552"
] | Nitazoxanide | Quazepam | Nitazoxanide belongs to the class of drugs known as _thiazolides_. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses.... | Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors a... | Moderate | 1 | [
[
[
316,
24,
481
]
],
[
[
316,
24,
1216
],
[
1216,
1,
481
]
],
[
[
316,
63,
905
],
[
905,
40,
481
]
],
[
[
316,
63,
1174
],
[
1174,
... | [
[
[
"Nitazoxanide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quazepam"
]
],
[
[
"Nitazoxanide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
],
[
... | Nitazoxanide may cause a moderate interaction that could exacerbate diseases when taken with Flurazepam and Flurazepam (Compound) resembles Quazepam (Compound)
Nitazoxanide may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound)
Ni... |
DB01129 | DB09280 | 379 | 1,604 | [
"DDInter1559",
"DDInter1101"
] | Rabeprazole | Lumacaftor | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
379,
24,
1604
]
],
[
[
379,
23,
1468
],
[
1468,
24,
1604
]
],
[
[
379,
64,
1195
],
[
1195,
24,
1604
]
],
[
[
379,
40,
837
],
[
837,
... | [
[
[
"Rabeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Rabeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
],
[
... | Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Rabeprazole may lead to a major life threatening interaction when taken with Erlotinib and Erlotinib may cause a mo... |
DB01234 | DB06207 | 1,220 | 910 | [
"DDInter513",
"DDInter1667"
] | Dexamethasone | Silodosin | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Silodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenocepto... | Moderate | 1 | [
[
[
1220,
24,
910
]
],
[
[
1220,
6,
8374
],
[
8374,
45,
910
]
],
[
[
1220,
21,
28921
],
[
28921,
60,
910
]
],
[
[
1220,
25,
484
],
[
484,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Silodosin"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Dexamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Silodosin (Compound)
Dexamethasone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Silodosin (Compound)
Dexamethasone may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib... |
DB00193 | DB09080 | 534 | 144 | [
"DDInter1841",
"DDInter1331"
] | Tramadol | Olodaterol | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
534,
24,
144
]
],
[
[
534,
25,
1011
],
[
1011,
24,
144
]
],
[
[
534,
24,
543
],
[
543,
24,
144
]
],
[
[
534,
24,
823
],
[
823,
6... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
... | Tramadol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a mo... |
DB00514 | DB00601 | 506 | 453 | [
"DDInter527",
"DDInter1073"
] | Dextromethorphan | Linezolid | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Major | 2 | [
[
[
506,
25,
453
]
],
[
[
506,
21,
28757
],
[
28757,
60,
453
]
],
[
[
506,
24,
272
],
[
272,
63,
453
]
],
[
[
506,
63,
999
],
[
999,
... | [
[
[
"Dextromethorphan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused b... | Dextromethorphan (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Linezolid (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases ... |
DB00087 | DB01101 | 599 | 60 | [
"DDInter41",
"DDInter285"
] | Alemtuzumab | Capecitabine | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
599,
24,
60
]
],
[
[
599,
24,
309
],
[
309,
62,
60
]
],
[
[
599,
24,
147
],
[
147,
23,
60
]
],
[
[
599,
24,
810
],
[
810,
63,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and V... |
DB00580 | DB09075 | 311 | 498 | [
"DDInter1910",
"DDInter621"
] | Valdecoxib | Edoxaban | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Moderate | 1 | [
[
[
311,
24,
498
]
],
[
[
311,
24,
1017
],
[
1017,
63,
498
]
],
[
[
311,
24,
129
],
[
129,
24,
498
]
],
[
[
311,
63,
305
],
[
305,
2... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalu... |
DB06589 | DB11866 | 1,250 | 1,068 | [
"DDInter1400",
"DDInter1618"
] | Pazopanib | Romosozumab | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
1250,
24,
1068
]
],
[
[
1250,
64,
1069
],
[
1069,
24,
1068
]
],
[
[
1250,
63,
1151
],
[
1151,
24,
1068
]
],
[
[
1250,
25,
1618
],
[
16... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib"... | Pazopanib may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a m... |
DB00673 | DB01259 | 723 | 392 | [
"DDInter112",
"DDInter1024"
] | Aprepitant | Lapatinib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
723,
24,
392
]
],
[
[
723,
10,
11579
],
[
11579,
44,
392
]
],
[
[
723,
6,
8374
],
[
8374,
45,
392
]
],
[
[
723,
21,
29429
],
[
29429,
... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Aprepitant",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) is tr... | Aprepitant (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound)
Aprepitant (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by La... |
DB00395 | DB00662 | 210 | 717 | [
"DDInter301",
"DDInter1873"
] | Carisoprodol | Trimethobenzamide | Originally approved by the FDA in 1959 [FDA label], carisoprodol is a centrally acting muscle relaxant used in painful musculoskeletal conditions in conjunction with physical therapy and other medications. This drug is available by itself in an oral tablet or combined with aspirin, or in a fixed-dose combination with b... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
210,
24,
717
]
],
[
[
210,
21,
28762
],
[
28762,
60,
717
]
],
[
[
210,
63,
1594
],
[
1594,
24,
717
]
],
[
[
210,
24,
13
],
[
13,
... | [
[
[
"Carisoprodol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Carisoprodol",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect... | Carisoprodol (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Carisoprodol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00289 | DB09241 | 847 | 1,629 | [
"DDInter132",
"DDInter1186"
] | Atomoxetine | Methylene blue | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
847,
25,
1629
]
],
[
[
847,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
847,
24,
1445
],
[
1445,
25,
1629
]
],
[
[
847,
40,
576
],
[
576,
... | [
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Is... | Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephed... |
DB00765 | DB01069 | 1,266 | 401 | [
"DDInter1205",
"DDInter1533"
] | Metyrosine | Promethazine | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1266,
24,
401
]
],
[
[
1266,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1266,
24,
104
],
[
104,
24,
401
]
],
[
[
1266,
21,
28662
],
[
28662,... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdila... |
DB00366 | DB01227 | 1,594 | 1,301 | [
"DDInter600",
"DDInter1043"
] | Doxylamine | Levacetylmethadol | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
1594,
36,
1301
]
],
[
[
1594,
74,
494
],
[
494,
1,
1301
]
],
[
[
1594,
24,
649
],
[
649,
1,
1301
]
],
[
[
1594,
36,
675
],
[
675,
... | [
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that co... | Doxylamine (Compound) resembles Levacetylmethadol (Compound) and
Doxylamine (Compound) resembles Disopyramide (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Doxylamine may cause a m... |
DB00013 | DB00881 | 1,255 | 954 | [
"DDInter1905",
"DDInter1554"
] | Urokinase | Quinapril | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Moderate | 1 | [
[
[
1255,
24,
954
]
],
[
[
1255,
24,
1638
],
[
1638,
1,
954
]
],
[
[
1255,
25,
365
],
[
365,
63,
954
]
],
[
[
1255,
24,
885
],
[
885,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril (Compound) resembles Quinapril (Compound)
Urokinase may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may cause a moderate interaction that could exacerbate di... |
DB01575 | DB11130 | 1,054 | 407 | [
"DDInter1005",
"DDInter1344"
] | Kaolin | Opium | Kaolin is a layered silicate mineral. Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics. Until the early 1990s it was the active substance of anti-diarrhoea medicine Kaopectate. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1054,
24,
407
]
],
[
[
1054,
62,
88
],
[
88,
24,
407
]
],
[
[
1054,
63,
576
],
[
576,
24,
407
]
],
[
[
1054,
23,
1592
],
[
1592,
... | [
[
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Kaolin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoprolol"
],
[
"Metoprolol... | Kaolin may cause a minor interaction that can limit clinical effects when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Opium
Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a ... |
DB01124 | DB01277 | 1,411 | 1,022 | [
"DDInter1828",
"DDInter1131"
] | Tolbutamide | Mecasermin | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label]. IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges and a molecular weight of 7649 daltons. The amino acid sequence of the product is identical to that of endogenous human I... | Moderate | 1 | [
[
[
1411,
24,
1022
]
],
[
[
1411,
63,
1179
],
[
1179,
24,
1022
]
],
[
[
1411,
1,
959
],
[
959,
24,
1022
]
],
[
[
1411,
24,
1296
],
[
1296,... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mecasermin"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin
Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction th... |
DB00741 | DB01174 | 167 | 697 | [
"DDInter885",
"DDInter1442"
] | Hydrocortisone | Phenobarbital | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Moderate | 1 | [
[
[
167,
24,
697
]
],
[
[
167,
24,
759
],
[
759,
1,
697
]
],
[
[
167,
63,
362
],
[
362,
1,
697
]
],
[
[
167,
63,
536
],
[
536,
40,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
]... | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (... |
DB00204 | DB00446 | 228 | 597 | [
"DDInter580",
"DDInter351"
] | Dofetilide | Chloramphenicol | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
228,
24,
597
]
],
[
[
228,
6,
8374
],
[
8374,
45,
597
]
],
[
[
228,
18,
4930
],
[
4930,
57,
597
]
],
[
[
228,
21,
29081
],
[
29081,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Dofetilide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chloramphenicol (Compound)
Dofetilide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Chloramphenicol (Compound)
Dofetilide (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Chloramphenicol ... |
DB00283 | DB01200 | 701 | 469 | [
"DDInter395",
"DDInter243"
] | Clemastine | Bromocriptine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
701,
24,
469
]
],
[
[
701,
6,
8374
],
[
8374,
45,
469
]
],
[
[
701,
18,
6797
],
[
6797,
57,
469
]
],
[
[
701,
21,
28898
],
[
28898,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Clemastine (Compound) downregulates CYCS (Gene) and CYCS (Gene) is downregulated by Bromocriptine (Compound)
Clemastine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Bromocriptine ... |
DB06791 | DB11703 | 1,446 | 405 | [
"DDInter1021",
"DDInter9"
] | Lanreotide | Acalabrutinib | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1446,
24,
405
]
],
[
[
1446,
63,
1324
],
[
1324,
24,
405
]
],
[
[
1446,
24,
951
],
[
951,
24,
405
]
],
[
[
1446,
24,
1375
],
[
1375,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib an... |
DB00163 | DB00444 | 1,461 | 63 | [
"DDInter1943",
"DDInter1765"
] | Vitamin E | Teniposide | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Moderate | 1 | [
[
[
1461,
24,
63
]
],
[
[
1461,
24,
147
],
[
147,
62,
63
]
],
[
[
1461,
24,
589
],
[
589,
63,
63
]
],
[
[
1461,
23,
1683
],
[
1683,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teniposide"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Teniposide
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin... |
DB01191 | DB01577 | 1,039 | 1,529 | [
"DDInter518",
"DDInter1161"
] | Dexfenfluramine | Metamfetamine | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Major | 2 | [
[
[
1039,
25,
1529
]
],
[
[
1039,
64,
939
],
[
939,
40,
1529
]
],
[
[
1039,
40,
11447
],
[
11447,
1,
1529
]
],
[
[
1039,
25,
93
],
[
93,
... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metamfetamine"
]
],
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzpheta... | Dexfenfluramine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Metamfetamine (Compound)
Dexfenfluramine (Compound) resembles Fenproporex (Compound) and Fenproporex (Compound) resembles Metamfetamine (Compound)
Dexfenfluramine may lead to a major lif... |
DB00099 | DB00322 | 440 | 141 | [
"DDInter735",
"DDInter742"
] | Filgrastim | Floxuridine | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Moderate | 1 | [
[
[
440,
24,
141
]
],
[
[
440,
24,
1083
],
[
1083,
40,
141
]
],
[
[
440,
25,
1064
],
[
1064,
25,
141
]
],
[
[
440,
24,
611
],
[
611,
... | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[... | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Floxuridine (Compound)
Filgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when... |
DB01230 | DB09268 | 795 | 1,662 | [
"DDInter1416",
"DDInter1464"
] | Pemoline | Picosulfuric acid | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
795,
24,
1662
]
],
[
[
795,
63,
912
],
[
912,
24,
1662
]
],
[
[
795,
64,
593
],
[
593,
24,
1662
]
],
[
[
795,
24,
1613
],
[
1613,
... | [
[
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Pemoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
... | Pemoline may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Pemoline may lead to a major life threatening interaction when taken with Bupropion and Bup... |
DB04868 | DB09143 | 478 | 313 | [
"DDInter1293",
"DDInter1701"
] | Nilotinib | Sonidegib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
478,
24,
313
]
],
[
[
478,
63,
1194
],
[
1194,
23,
313
]
],
[
[
478,
24,
101
],
[
101,
23,
313
]
],
[
[
478,
24,
1478
],
[
1478,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole and Dexlan... |
DB01124 | DB01403 | 1,411 | 9 | [
"DDInter1828",
"DDInter1175"
] | Tolbutamide | Methotrimeprazine | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1411,
24,
9
]
],
[
[
1411,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1411,
63,
1164
],
[
1164,
1,
9
]
],
[
[
1411,
63,
401
],
[
401,
24... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles... |
DB00902 | DB01192 | 104 | 560 | [
"DDInter1168",
"DDInter1372"
] | Methdilazine | Oxymorphone | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
104,
24,
560
]
],
[
[
104,
63,
828
],
[
828,
1,
560
]
],
[
[
104,
63,
1123
],
[
1123,
24,
560
]
],
[
[
104,
40,
820
],
[
820,
63... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction t... |
DB00069 | DB00446 | 367 | 597 | [
"DDInter946",
"DDInter351"
] | Interferon alfacon-1 | Chloramphenicol | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
367,
24,
597
]
],
[
[
367,
25,
1101
],
[
1101,
23,
597
]
],
[
[
367,
24,
1627
],
[
1627,
62,
597
]
],
[
[
367,
23,
450
],
[
450,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
]... | Interferon alfacon-1 may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol a... |
DB00218 | DB00620 | 1,176 | 175 | [
"DDInter1247",
"DDInter1855"
] | Moxifloxacin | Triamcinolone | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Major | 2 | [
[
[
1176,
25,
175
]
],
[
[
1176,
25,
1573
],
[
1573,
1,
175
]
],
[
[
1176,
21,
28661
],
[
28661,
60,
175
]
],
[
[
1176,
24,
455
],
[
455,
... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
],
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
... | Moxifloxacin may lead to a major life threatening interaction when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Moxifloxacin (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Triamcinolone (Compound)
Moxifloxacin may caus... |
DB00202 | DB00531 | 190 | 450 | [
"DDInter1716",
"DDInter456"
] | Succinylcholine | Cyclophosphamide | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Moderate | 1 | [
[
[
190,
24,
450
]
],
[
[
190,
21,
28841
],
[
28841,
60,
450
]
],
[
[
190,
24,
1287
],
[
1287,
63,
450
]
],
[
[
190,
24,
770
],
[
770,
... | [
[
[
"Succinylcholine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Bronchospasm"
],
[
"Bronchospasm",
"{u}... | Succinylcholine (Compound) causes Bronchospasm (Side Effect) and Bronchospasm (Side Effect) is caused by Cyclophosphamide (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate di... |
DB01095 | DB12130 | 671 | 1,017 | [
"DDInter769",
"DDInter1094"
] | Fluvastatin | Lorlatinib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
671,
24,
1017
]
],
[
[
671,
24,
14
],
[
14,
24,
1017
]
],
[
[
671,
62,
126
],
[
126,
24,
1017
]
],
[
[
671,
63,
888
],
[
888,
24... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warf... |
DB00197 | DB06788 | 1,324 | 1,616 | [
"DDInter1881",
"DDInter864"
] | Troglitazone | Histrelin | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1324,
24,
1616
]
],
[
[
1324,
24,
1664
],
[
1664,
24,
1616
]
],
[
[
1324,
63,
1179
],
[
1179,
24,
1616
]
],
[
[
1324,
24,
927
],
[
927... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro a... |
DB00771 | DB04843 | 262 | 1,511 | [
"DDInter397",
"DDInter1149"
] | Clidinium | Mepenzolate | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
262,
24,
1511
]
],
[
[
262,
74,
675
],
[
675,
24,
1511
]
],
[
[
262,
24,
537
],
[
537,
24,
1511
]
],
[
[
262,
40,
1413
],
[
1413,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken wi... | Clidinium (Compound) resembles Dextropropoxyphene (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Clidinium may cause a moderate ... |
DB00209 | DB00792 | 352 | 832 | [
"DDInter1886",
"DDInter1878"
] | Trospium | Tripelennamine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
352,
24,
832
]
],
[
[
352,
24,
100
],
[
100,
63,
832
]
],
[
[
352,
24,
508
],
[
508,
1,
832
]
],
[
[
352,
24,
1594
],
[
1594,
24... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Promazine a... |
DB00191 | DB00333 | 73 | 576 | [
"DDInter1447",
"DDInter1166"
] | Phentermine | Methadone | Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows thi... | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
73,
24,
576
]
],
[
[
73,
25,
939
],
[
939,
40,
576
]
],
[
[
73,
24,
1164
],
[
1164,
1,
576
]
],
[
[
73,
24,
146
],
[
146,
40,
... | [
[
[
"Phentermine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Benzphetamine"
],
[
"Benzph... | Phentermine may lead to a major life threatening interaction when taken with Benzphetamine and Benzphetamine (Compound) resembles Methadone (Compound)
Phentermine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Methadone (Compound)
Phent... |
DB00710 | DB11110 | 1,199 | 603 | [
"DDInter897",
"DDInter1115"
] | Ibandronate | Magnesium citrate | Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to [zoledronic acid], [minodronic acid], and [risedronic acid].[A203111,A203138] It is used to prevent and treat postmenopausal osteoporosis.[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatm... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
1199,
24,
603
]
],
[
[
1199,
24,
1151
],
[
1151,
24,
603
]
],
[
[
1199,
1,
1008
],
[
1008,
24,
603
]
],
[
[
1199,
63,
544
],
[
544,
... | [
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Ibandronate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
... | Ibandronate may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Ibandronate (Compound) resembles Risedronic acid (Compound) and Risedronic acid may cause a moderate inter... |
DB00030 | DB02546 | 1,685 | 137 | [
"DDInter934",
"DDInter1947"
] | Insulin human | Vorinostat | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
1685,
24,
137
]
],
[
[
1685,
24,
127
],
[
127,
24,
137
]
],
[
[
1685,
24,
1344
],
[
1344,
63,
137
]
],
[
[
1685,
24,
127
],
[
127,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Vorinostat
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and C... |
DB00381 | DB14724 | 376 | 48 | [
"DDInter79",
"DDInter634"
] | Amlodipine | Emapalumab | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority... | Moderate | 1 | [
[
[
376,
24,
48
]
],
[
[
376,
40,
854
],
[
854,
24,
48
]
],
[
[
376,
24,
1409
],
[
1409,
24,
48
]
],
[
[
376,
1,
1081
],
[
1081,
24,... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Emapalumab"
]
],
[
[
"Amlodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nimodipine"
],
[
"Nimodipine",
"{u} may cause a moderat... | Amlodipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Emapalumab
Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may cause a moderate interaction that could exa... |
DB00629 | DB06292 | 390 | 549 | [
"DDInter844",
"DDInter474"
] | Guanabenz | Dapagliflozin | An alpha-2 selective adrenergic agonist used as an antihypertensive agent. [PubChem] | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
390,
24,
549
]
],
[
[
390,
24,
1344
],
[
1344,
40,
549
]
],
[
[
390,
6,
7950
],
[
7950,
45,
549
]
],
[
[
390,
21,
29222
],
[
29222,
... | [
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Guanabenz",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
... | Guanabenz may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Guanabenz (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Dapagliflozin (Compound)
Guanabenz (Compound) causes Hypoglycaemia (Side Effect) ... |
DB00197 | DB00903 | 1,324 | 1,680 | [
"DDInter1881",
"DDInter686"
] | Troglitazone | Etacrynic acid | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
1324,
24,
1680
]
],
[
[
1324,
24,
222
],
[
222,
63,
1680
]
],
[
[
1324,
63,
1179
],
[
1179,
24,
1680
]
],
[
[
1324,
24,
126
],
[
126,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin lis... |
DB00364 | DB00586 | 417 | 1,512 | [
"DDInter1717",
"DDInter537"
] | Sucralfate | Diclofenac | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Minor | 0 | [
[
[
417,
23,
1512
]
],
[
[
417,
6,
1829
],
[
1829,
45,
1512
]
],
[
[
417,
21,
28775
],
[
28775,
60,
1512
]
],
[
[
417,
24,
255
],
[
255,
... | [
[
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
]
],
[
[
"Sucralfate",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"... | Sucralfate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Diclofenac (Compound)
Sucralfate (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Diclofenac (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Delafloxacin and Delaflox... |
DB00363 | DB00902 | 695 | 104 | [
"DDInter419",
"DDInter1168"
] | Clozapine | Methdilazine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
695,
24,
104
]
],
[
[
695,
35,
13
],
[
13,
24,
104
]
],
[
[
695,
25,
820
],
[
820,
1,
104
]
],
[
[
695,
24,
537
],
[
537,
40,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Clozapine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Clozapine (Compound) resembles Cyproheptadine (Compound) and Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Clozapine may lead to a major life threate... |
DB00193 | DB01177 | 534 | 77 | [
"DDInter1841",
"DDInter904"
] | Tramadol | Idarubicin | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
534,
24,
77
]
],
[
[
534,
6,
12523
],
[
12523,
45,
77
]
],
[
[
534,
7,
8779
],
[
8779,
46,
77
]
],
[
[
534,
18,
18226
],
[
18226,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Tramadol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Tramadol (Compound) upregulates CERK (Gene) and CERK (Gene) is upregulated by Idarubicin (Compound)
Tramadol (Compound) downregulates GDF15 (Gene) and GDF15 (Gene) is downregulated by Idarubicin (Compound)
Tramadol (Compound) ca... |
DB00307 | DB12825 | 1,101 | 1,375 | [
"DDInter202",
"DDInter1032"
] | Bexarotene | Lefamulin | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1101,
24,
1375
]
],
[
[
1101,
24,
159
],
[
159,
63,
1375
]
],
[
[
1101,
64,
966
],
[
966,
24,
1375
]
],
[
[
1101,
24,
309
],
[
309,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Bexarotene may lead to a major life threatening interaction when taken with Octreotide and Octreotide may c... |
DB00872 | DB04845 | 1,080 | 309 | [
"DDInter438",
"DDInter1001"
] | Conivaptan | Ixabepilone | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1080,
24,
309
]
],
[
[
1080,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1080,
21,
28736
],
[
28736,
60,
309
]
],
[
[
1080,
63,
1419
],
[
1419... | [
[
[
"Conivaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Conivaptan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Conivaptan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Conivaptan (Compound) causes Dehydration (Side Effect) and Dehydration (Side Effect) is caused by Ixabepilone (Compound)
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and ... |
DB00928 | DB10429 | 1,426 | 200 | [
"DDInter148",
"DDInter282"
] | Azacitidine | Candida albicans | Azacitidine is a pyrimidine nucleoside analogue with anti-neoplastic activity. It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine. One of them is the induction of cytotoxicity. ... | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1426,
24,
200
]
],
[
[
1426,
24,
1683
],
[
1683,
24,
200
]
],
[
[
1426,
25,
976
],
[
976,
24,
200
]
],
[
[
1426,
1,
1488
],
[
1488,
... | [
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Azacitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],... | Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Azacitidine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitini... |
DB00476 | DB00514 | 109 | 506 | [
"DDInter608",
"DDInter527"
] | Duloxetine | Dextromethorphan | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Major | 2 | [
[
[
109,
25,
506
]
],
[
[
109,
6,
6112
],
[
6112,
45,
506
]
],
[
[
109,
21,
28750
],
[
28750,
60,
506
]
],
[
[
109,
24,
741
],
[
741,
... | [
[
[
"Duloxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"SLC6A4"
],
[
"SLC6A4",
"{u} (Gene) is bound by {v} (Compound)",
"D... | Duloxetine (Compound) binds SLC6A4 (Gene) and SLC6A4 (Gene) is bound by Dextromethorphan (Compound)
Duloxetine (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Dextromethorphan (Compound)
Duloxetine may cause a moderate interaction that could exacerbate diseases w... |
DB01233 | DB06077 | 1,311 | 879 | [
"DDInter1197",
"DDInter1102"
] | Metoclopramide | Lumateperone | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Major | 2 | [
[
[
1311,
25,
879
]
],
[
[
1311,
24,
1374
],
[
1374,
24,
879
]
],
[
[
1311,
24,
407
],
[
407,
63,
879
]
],
[
[
1311,
63,
537
],
[
537,
... | [
[
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumateperone"
]
],
[
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
... | Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Opium and... |
DB11730 | DB15093 | 351 | 1,654 | [
"DDInter1588",
"DDInter1698"
] | Ribociclib | Somapacitan | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
351,
24,
1654
]
],
[
[
351,
63,
10
],
[
10,
24,
1654
]
],
[
[
351,
64,
1135
],
[
1135,
24,
1654
]
],
[
[
351,
25,
1019
],
[
1019,
... | [
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
],
[
... | Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a moder... |
DB00376 | DB09272 | 1,105 | 412 | [
"DDInter1870",
"DDInter632"
] | Trihexyphenidyl | Eluxadoline | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1105,
24,
412
]
],
[
[
1105,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1105,
24,
543
],
[
543,
24,
412
]
],
[
[
1105,
35,
1192
],
[
1192,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Loperamide... |
DB00431 | DB04946 | 1,503 | 924 | [
"DDInter1072",
"DDInter907"
] | Lindane | Iloperidone | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1503,
24,
924
]
],
[
[
1503,
24,
1664
],
[
1664,
1,
924
]
],
[
[
1503,
24,
519
],
[
519,
40,
924
]
],
[
[
1503,
21,
28787
],
[
28787,
... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
[
... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone (Compound... |
DB06335 | DB08816 | 761 | 578 | [
"DDInter1646",
"DDInter1802"
] | Saxagliptin | Ticagrelor | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
761,
24,
578
]
],
[
[
761,
6,
8374
],
[
8374,
45,
578
]
],
[
[
761,
21,
28646
],
[
28646,
60,
578
]
],
[
[
761,
63,
336
],
[
336,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Saxagliptin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Saxagliptin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ticagrelor (Compound)
Saxagliptin (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Ticagrelor (Compound)
Saxagliptin may cause ... |
DB00496 | DB01246 | 194 | 820 | [
"DDInter480",
"DDInter45"
] | Darifenacin | Alimemazine | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
194,
24,
820
]
],
[
[
194,
24,
104
],
[
104,
40,
820
]
],
[
[
194,
24,
401
],
[
401,
24,
820
]
],
[
[
194,
6,
8374
],
[
8374,
45... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction... |
DB00754 | DB00787 | 157 | 387 | [
"DDInter696",
"DDInter25"
] | Ethotoin | Acyclovir | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, _Varicella zoster_, herpes zoster, herpes labialis, and acute herpetic keratitis[L7303,L7315,L7318,L7321,L7324,L7327]. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young a... | Moderate | 1 | [
[
[
157,
24,
387
]
],
[
[
157,
18,
6351
],
[
6351,
57,
387
]
],
[
[
157,
21,
28882
],
[
28882,
60,
387
]
],
[
[
157,
23,
1096
],
[
1096,
... | [
[
[
"Ethotoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acyclovir"
]
],
[
[
"Ethotoin",
"{u} (Compound) downregulates {v} (Gene)",
"COTL1"
],
[
"COTL1",
"{u} (Gene) is downregulated by {v} (Co... | Ethotoin (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Acyclovir (Compound)
Ethotoin (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Acyclovir (Compound)
Ethotoin may cause a minor interaction that can limit clinical effec... |
DB05351 | DB12615 | 101 | 1,381 | [
"DDInter519",
"DDInter1482"
] | Dexlansoprazole | Plazomicin | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
101,
24,
1381
]
],
[
[
101,
62,
1479
],
[
1479,
24,
1381
]
],
[
[
101,
63,
416
],
[
416,
24,
1381
]
],
[
[
101,
64,
663
],
[
663,
... | [
[
[
"Dexlansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic aci... | Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Plazomicin
Dexlansoprazole may cause a moderate interaction that could exacerbate diseases when take... |
DB00206 | DB00242 | 1,245 | 1,064 | [
"DDInter1582",
"DDInter392"
] | Reserpine | Cladribine | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Moderate | 1 | [
[
[
1245,
24,
1064
]
],
[
[
1245,
6,
10715
],
[
10715,
45,
1064
]
],
[
[
1245,
18,
6248
],
[
6248,
45,
1064
]
],
[
[
1245,
7,
3361
],
[
33... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
]
],
[
[
"Reserpine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A1"
],
[
"SLC22A1",
"{u} (Gene) is bound by {v} (Compound)",... | Reserpine (Compound) binds SLC22A1 (Gene) and SLC22A1 (Gene) is bound by Cladribine (Compound)
Reserpine (Compound) downregulates DCK (Gene) and DCK (Gene) is bound by Cladribine (Compound)
Reserpine (Compound) upregulates NFIL3 (Gene) and NFIL3 (Gene) is upregulated by Cladribine (Compound)
Reserpine (Compound) downre... |
DB00356 | DB00434 | 1,315 | 13 | [
"DDInter366",
"DDInter459"
] | Chlorzoxazone | Cyproheptadine | A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202) | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
1315,
24,
13
]
],
[
[
1315,
24,
537
],
[
537,
63,
13
]
],
[
[
1315,
21,
28705
],
[
28705,
60,
13
]
],
[
[
1315,
24,
128
],
[
128,
... | [
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Chlorzoxazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],... | Chlorzoxazone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Chlorzoxazone (Compound) causes Drowsiness (Side Effect) and Drowsiness (Side Effect) is caused by Cyprohep... |
DB01168 | DB01619 | 1,053 | 830 | [
"DDInter1526",
"DDInter1441"
] | Procarbazine | Phenindamine | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
1053,
24,
830
]
],
[
[
1053,
64,
1251
],
[
1251,
1,
830
]
],
[
[
1053,
24,
537
],
[
537,
40,
830
]
],
[
[
1053,
63,
1219
],
[
1219,
... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mirtazapine"
],
[
"Mir... | Procarbazine may lead to a major life threatening interaction when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Procarb... |
DB09293 | DB11989 | 116 | 1,434 | [
"DDInter954",
"DDInter183"
] | Iodide I-131 | Benznidazole | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
116,
24,
1434
]
],
[
[
116,
24,
148
],
[
148,
63,
1434
]
],
[
[
116,
63,
505
],
[
505,
24,
1434
]
],
[
[
116,
64,
33
],
[
33,
24... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
],
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole and Secnidazole may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxy... |
DB00575 | DB08895 | 1,020 | 976 | [
"DDInter412",
"DDInter1825"
] | Clonidine | Tofacitinib | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1020,
24,
976
]
],
[
[
1020,
24,
407
],
[
407,
63,
976
]
],
[
[
1020,
63,
475
],
[
475,
24,
976
]
],
[
[
1020,
1,
1512
],
[
1512,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"O... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause ... |
DB00158 | DB01320 | 356 | 651 | [
"DDInter771",
"DDInter783"
] | Folic acid | Fosphenytoin | Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic aci... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
356,
24,
651
]
],
[
[
356,
24,
362
],
[
362,
1,
651
]
],
[
[
356,
21,
28708
],
[
28708,
60,
651
]
],
[
[
356,
1,
1147
],
[
1147,
... | [
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Folic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Folic acid may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Folic acid (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is caused by Fosphenytoin (Compound)
Folic acid (Compound) resembles Leucovorin (Co... |
DB01403 | DB06655 | 9 | 5 | [
"DDInter1175",
"DDInter1077"
] | Methotrimeprazine | Liraglutide | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
9,
24,
5
]
],
[
[
9,
63,
245
],
[
245,
24,
5
]
],
[
[
9,
40,
1630
],
[
1630,
24,
5
]
],
[
[
9,
1,
216
],
[
216,
24,
5
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Methotrimeprazine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate i... |
DB06274 | DB12010 | 574 | 214 | [
"DDInter59",
"DDInter785"
] | Alvimopan | Fostamatinib | Alvimopan is a peripherally acting μ opioid antagonist. It is used to avoid postoperative ileus following small or large bowel resection and accelerates the gastrointestinal recovery period. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
574,
24,
214
]
],
[
[
574,
63,
540
],
[
540,
24,
214
]
],
[
[
574,
64,
576
],
[
576,
24,
214
]
],
[
[
574,
25,
180
],
[
180,
63,... | [
[
[
"Alvimopan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Alvimopan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
... | Alvimopan may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Alvimopan may lead to a major life threatening interaction when taken with Methadone and Methadone may cause ... |
DB00427 | DB00690 | 1,233 | 1,216 | [
"DDInter1879",
"DDInter762"
] | Triprolidine | Flurazepam | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
1233,
24,
1216
]
],
[
[
1233,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
1233,
24,
481
],
[
481,
40,
1216
]
],
[
[
1233,
63,
902
],
[
902,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Tr... |
DB00069 | DB14761 | 367 | 242 | [
"DDInter946",
"DDInter1578"
] | Interferon alfacon-1 | Remdesivir | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
367,
24,
242
]
],
[
[
367,
24,
467
],
[
467,
24,
242
]
],
[
[
367,
25,
1377
],
[
1377,
24,
242
]
],
[
[
367,
63,
491
],
[
491,
2... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvast... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Leflunomide an... |
DB00308 | DB08868 | 347 | 1,011 | [
"DDInter901",
"DDInter737"
] | Ibutilide | Fingolimod | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
347,
25,
1011
]
],
[
[
347,
21,
28859
],
[
28859,
60,
1011
]
],
[
[
347,
23,
112
],
[
112,
23,
1011
]
],
[
[
347,
24,
144
],
[
144,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Atrioventricular block"
],
[
"Atrioventricular block",
"{u} (Side Effect... | Ibutilide (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effec... |
DB00086 | DB06228 | 1,167 | 792 | [
"DDInter1712",
"DDInter1609"
] | Streptokinase | Rivaroxaban | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Major | 2 | [
[
[
1167,
25,
792
]
],
[
[
1167,
23,
944
],
[
944,
62,
792
]
],
[
[
1167,
24,
901
],
[
901,
24,
792
]
],
[
[
1167,
24,
738
],
[
738,
... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamom... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Rivaroxaban
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Miln... |
DB00213 | DB09100 | 837 | 320 | [
"DDInter1388",
"DDInter1799"
] | Pantoprazole | Thyroid, porcine | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Moderate | 1 | [
[
[
837,
24,
320
]
],
[
[
837,
24,
467
],
[
467,
23,
320
]
],
[
[
837,
1,
379
],
[
379,
24,
320
]
],
[
[
837,
24,
428
],
[
428,
63,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thyroid, porcine"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Thyroid, porcine
Pantoprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interactio... |
DB01268 | DB12245 | 1,151 | 823 | [
"DDInter1731",
"DDInter1863"
] | Sunitinib | Triclabendazole | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1151,
24,
823
]
],
[
[
1151,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1151,
24,
1612
],
[
1612,
24,
823
]
],
[
[
1151,
63,
1010
],
[
1010,... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavi... |
DB00687 | DB15091 | 870 | 676 | [
"DDInter747",
"DDInter1901"
] | Fludrocortisone | Upadacitinib | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
870,
25,
676
]
],
[
[
870,
24,
1430
],
[
1430,
24,
676
]
],
[
[
870,
24,
1654
],
[
1654,
63,
676
]
],
[
[
870,
63,
600
],
[
600,
... | [
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Somap... |
DB00468 | DB00673 | 1,424 | 723 | [
"DDInter1557",
"DDInter112"
] | Quinine | Aprepitant | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1424,
24,
723
]
],
[
[
1424,
24,
875
],
[
875,
40,
723
]
],
[
[
1424,
6,
7950
],
[
7950,
45,
723
]
],
[
[
1424,
21,
28642
],
[
28642,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Quinine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Quinine (Compound) causes Shock (Side Effect) and Shock (Side Effe... |
DB00195 | DB00983 | 726 | 480 | [
"DDInter198",
"DDInter776"
] | Betaxolol (ophthalmic) | Formoterol | Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
726,
24,
480
]
],
[
[
726,
24,
1148
],
[
1148,
63,
480
]
],
[
[
726,
6,
1704
],
[
1704,
45,
480
]
],
[
[
726,
21,
28963
],
[
28963,
... | [
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Betaxolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Betaxolol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Betaxolo... |
DB00241 | DB00277 | 288 | 1,031 | [
"DDInter257",
"DDInter1791"
] | Butalbital | Theophylline | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under seve... | Moderate | 1 | [
[
[
288,
24,
1031
]
],
[
[
288,
24,
516
],
[
516,
62,
1031
]
],
[
[
288,
24,
1152
],
[
1152,
63,
1031
]
],
[
[
288,
1,
536
],
[
536,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a minor interaction that can limit clinical effects when taken with Theophylline
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine ... |
DB00377 | DB00489 | 1,494 | 17 | [
"DDInter1382",
"DDInter1704"
] | Palonosetron | Sotalol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Major | 2 | [
[
[
1494,
25,
17
]
],
[
[
1494,
64,
347
],
[
347,
40,
17
]
],
[
[
1494,
21,
28719
],
[
28719,
60,
17
]
],
[
[
1494,
23,
112
],
[
112,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (C... | Palonosetron may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Sotalol (Compound)
Palonosetron (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Sotalol (Compound)
Palonosetron may cause a minor interaction that can limit clinical effect... |
DB00675 | DB12130 | 888 | 1,017 | [
"DDInter1744",
"DDInter1094"
] | Tamoxifen | Lorlatinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
888,
24,
1017
]
],
[
[
888,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
888,
25,
271
],
[
271,
23,
1017
]
],
[
[
888,
63,
1101
],
[
1101,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Tamoxifen may lead to a major life threatening interaction when taken with Mirabegron and Mirabegron may cause a ... |
DB06824 | DB11126 | 29 | 900 | [
"DDInter1864",
"DDInter276"
] | Triethylenetetramine | Calcium gluconate | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
29,
24,
900
]
],
[
[
29,
23,
1193
],
[
1193,
63,
246
],
[
246,
24,
900
]
],
[
[
29,
24,
636
],
[
636,
63,
819
],
[
819,
24,
90... | [
[
[
"Triethylenetetramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Triethylenetetramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zi... | Triethylenetetramine may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a moderate interaction that could exacerbate diseases when taken with Gatifloxacin and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00373 | DB08865 | 461 | 1,593 | [
"DDInter1809",
"DDInter448"
] | Timolol | Crizotinib | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
461,
24,
1593
]
],
[
[
461,
6,
4973
],
[
4973,
45,
1593
]
],
[
[
461,
7,
6952
],
[
6952,
46,
1593
]
],
[
[
461,
21,
28771
],
[
28771,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Timolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Crizotinib (Compound)
Timolol (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Crizotinib (Compound)
Timolol (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compo... |
DB00381 | DB01240 | 376 | 885 | [
"DDInter79",
"DDInter657"
] | Amlodipine | Epoprostenol | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
376,
24,
885
]
],
[
[
376,
63,
1061
],
[
1061,
1,
885
]
],
[
[
376,
6,
6017
],
[
6017,
45,
885
]
],
[
[
376,
21,
28684
],
[
28684,
... | [
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Amlodipine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Epoprostenol (Compound)
Amlodipine (Compound) causes Hypoaesthesia (Side Effect) a... |
DB01006 | DB06448 | 300 | 171 | [
"DDInter1040",
"DDInter1087"
] | Letrozole | Lonafarnib | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
300,
24,
171
]
],
[
[
300,
63,
1347
],
[
1347,
24,
171
]
],
[
[
300,
24,
98
],
[
98,
63,
171
]
],
[
[
300,
24,
187
],
[
187,
24,... | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem... |
DB01024 | DB10989 | 1,096 | 496 | [
"DDInter1252",
"DDInter858"
] | Mycophenolic acid | Hepatitis A Vaccine | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1096,
24,
496
]
],
[
[
1096,
24,
4
],
[
4,
24,
496
]
],
[
[
1096,
25,
976
],
[
976,
24,
496
]
],
[
[
1096,
24,
270
],
[
270,
63,... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omac... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Mycophenolic acid may lead to a major life threatening interaction... |
DB00927 | DB01064 | 1,559 | 1,148 | [
"DDInter712",
"DDInter987"
] | Famotidine | Isoprenaline | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1559,
24,
1148
]
],
[
[
1559,
24,
480
],
[
480,
24,
1148
]
],
[
[
1559,
21,
28717
],
[
28717,
60,
1148
]
],
[
[
1559,
63,
534
],
[
534... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Famotidine (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Isoprenaline (Comp... |
DB00747 | DB00899 | 1,442 | 411 | [
"DDInter1647",
"DDInter1579"
] | Scopolamine | Remifentanil | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist which means it reduces sympathetic nervous system tone, and causes respiratory depress... | Moderate | 1 | [
[
[
1442,
24,
411
]
],
[
[
1442,
24,
1322
],
[
1322,
40,
411
]
],
[
[
1442,
24,
704
],
[
704,
1,
411
]
],
[
[
1442,
63,
1454
],
[
1454,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remifentanil"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil (Compound) resembles Remifentanil (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Remifentanil (Compound... |
DB00361 | DB12130 | 134 | 1,017 | [
"DDInter1939",
"DDInter1094"
] | Vinorelbine | Lorlatinib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
134,
24,
1017
]
],
[
[
134,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
134,
25,
976
],
[
976,
24,
1017
]
],
[
[
134,
24,
1554
],
[
1554,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Vinorelbine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may caus... |
DB01377 | DB01396 | 1,283 | 1,482 | [
"DDInter1119",
"DDInter553"
] | Magnesium oxide | Digitoxin | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Minor | 0 | [
[
[
1283,
23,
1482
]
],
[
[
1283,
62,
1252
],
[
1252,
1,
1482
]
],
[
[
1283,
24,
286
],
[
286,
62,
1482
]
],
[
[
1283,
62,
752
],
[
752,
... | [
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digitoxin"
]
],
[
[
"Magnesium oxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
... | Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor intera... |
DB00377 | DB00502 | 1,494 | 1,300 | [
"DDInter1382",
"DDInter853"
] | Palonosetron | Haloperidol | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Major | 2 | [
[
[
1494,
25,
1300
]
],
[
[
1494,
25,
78
],
[
78,
1,
1300
]
],
[
[
1494,
24,
543
],
[
543,
63,
1300
]
],
[
[
1494,
6,
8374
],
[
8374,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"... | Palonosetron may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Haloperidol (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbat... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.